CBD Shows Promise for Anxiety and Sleep, But Evidence Quality Varies Widely
A scoping review of 29 studies found that cannabinoids, particularly CBD, showed potential for improving both anxiety and sleep disturbances, but major differences in study design and dosing limit conclusions.
Quick Facts
What This Study Found
Of 29 studies meeting inclusion criteria, about 45% reported positive effects on both anxiety and sleep outcomes. CBD was the most commonly studied cannabinoid with the most consistent positive results. However, substantial heterogeneity in study design, cannabinoid types, dosing regimens, and outcome measures limited the ability to draw definitive conclusions or establish standardized dosing.
Key Numbers
1,132 documents retrieved, 29 met inclusion criteria. ~45% reported positive effects on both anxiety and sleep. Scientific literature on medical cannabis for these conditions increased approximately 15-fold in the last decade. CBD was the cannabinoid with the most consistent evidence.
How They Did This
Scoping review searching PubMed, EMBASE, Cochrane, CINAHL, LILACS, and PsycINFO. From 1,132 retrieved documents, 29 met inclusion criteria, including RCTs, observational studies, and case series. Quality assessment was conducted for each study.
Why This Research Matters
At least 60% of people with anxiety disorders also have sleep problems, and both conditions share physiological mechanisms. CBD's potential to address both simultaneously would be clinically valuable, but this review shows the evidence base needs more rigorous, standardized research to support clinical recommendations.
The Bigger Picture
The rapid growth in cannabis research (15-fold in a decade) reflects both public interest and scientific recognition of cannabinoids' therapeutic potential. However, the field has been hampered by inconsistent methodologies, making it difficult to translate promising findings into clinical practice. Standardized dosing protocols and outcome measures are urgently needed.
What This Study Doesn't Tell Us
Scoping review has inherent limitations compared to systematic reviews with meta-analysis. Heterogeneous study designs prevent quantitative pooling of results. Many included studies were small or observational. Positive publication bias may inflate the apparent efficacy.
Questions This Raises
- ?What is the optimal CBD dose for combined anxiety-sleep benefits?
- ?How do different cannabinoid formulations compare in efficacy?
- ?Would standardized outcome measures in future studies allow for meaningful meta-analysis?
Trust & Context
- Key Stat:
- 45% of studies reported positive effects on both anxiety and sleep
- Evidence Grade:
- Moderate evidence strength for the field overall based on 29 studies, though heterogeneity limits the strength of any individual conclusion.
- Study Age:
- 2025 scoping review covering the current state of cannabinoid research for anxiety and sleep.
- Original Title:
- Cannabinoids for Anxiety and Sleep Disturbances: A Scoping Review.
- Published In:
- Medical cannabis and cannabinoids, 8(1), 219-237 (2025)
- Authors:
- Perez, Juan G(2), LaMontagne, Liva G, Garcia, Gabriela A, Vaddiparti, Krishna, Gupta, Pranav S, Churba, Benjamin Z, Hossain, Ryan, Lopez-Quintero, Catalina
- Database ID:
- RTHC-07349
Evidence Hierarchy
Maps out the available research on a broad question.
What do these levels mean? →Frequently Asked Questions
Does CBD help with anxiety and sleep?
About 45% of the 29 studies reviewed reported positive effects on both anxiety and sleep. CBD was the cannabinoid with the most consistent evidence. However, differences in dosing, formulations, and study designs mean there is not yet enough evidence to establish standardized treatment protocols.
Why isn't there a clear answer yet?
The research field has grown rapidly but lacks consistency. Studies use different cannabinoid types, doses, and ways of measuring outcomes. Future research needs standardized methods, including dose-response studies, to provide the clear evidence needed for clinical guidelines.
Read More on RethinkTHC
- anxiety-leaving-house-weed-withdrawal-agoraphobia
- anxiety-response-technique-weed-withdrawal
- anxiety-toolkit-weed-withdrawal
- anxiety-worse-after-quitting-weed
- breathing-exercises-weed-withdrawal-anxiety
- cannabis-induced-anxiety
- does-weed-help-anxiety
- grounding-techniques-weed-withdrawal
- health-anxiety-weed-withdrawal
- manage-anxiety-without-weed
- quitting-weed-anxiety-disorder
- quitting-weed-anxiety-medication-ssri
- self-medicating-anxiety-with-weed
- therapy-quitting-weed-anxiety
- weed-and-anxiety
- weed-biphasic-effect-anxiety
- weed-generalized-anxiety-disorder
- weed-panic-attacks
- weed-paranoia
- weed-social-anxiety
- weed-tolerance-anxiety-stopped-working
- weed-withdrawal-anxiety
- weed-withdrawal-panic-attacks-night
- weed-withdrawal-work-anxiety
- withdrawal-anxiety-vs-real-anxiety
Cite This Study
https://rethinkthc.com/research/RTHC-07349APA
Perez, Juan G; LaMontagne, Liva G; Garcia, Gabriela A; Vaddiparti, Krishna; Gupta, Pranav S; Churba, Benjamin Z; Hossain, Ryan; Lopez-Quintero, Catalina. (2025). Cannabinoids for Anxiety and Sleep Disturbances: A Scoping Review.. Medical cannabis and cannabinoids, 8(1), 219-237. https://doi.org/10.1159/000548890
MLA
Perez, Juan G, et al. "Cannabinoids for Anxiety and Sleep Disturbances: A Scoping Review.." Medical cannabis and cannabinoids, 2025. https://doi.org/10.1159/000548890
RethinkTHC
RethinkTHC Research Database. "Cannabinoids for Anxiety and Sleep Disturbances: A Scoping R..." RTHC-07349. Retrieved from https://rethinkthc.com/research/perez-2025-cannabinoids-for-anxiety-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.